HARMONY BIOSCIENCES HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.44% for the 12-month period ending 2025-12-31, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-04
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-03-31 was 4.44%, a 5.71% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-03-31 was 4.20%, a 15.70% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-03-31 was 3.63%, a 53.16% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2022-03-31 was 2.37%, a 99.16% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.65%, a 0.65% increase from fiscal 2023.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.62%, a 14.07% increase from fiscal 2022.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.05%, a 181.25% increase from fiscal 2021.
- HARMONY BIOSCIENCES HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2021 was 1.44%, a 157.14% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.44% 10-Q · filed 2026-08-04 | |||
| 2025-09-30 | 4.44% 10-Q · filed 2025-11-04 | |||
| 2025-03-31 | 4.44% 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | 4.65% 10-K · filed 2026-02-24 | |||
| 2024-09-30 | 4.65% 10-Q · filed 2024-10-29 | |||
| 2024-06-30 | 4.65% 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | 4.20% 10-Q · filed 2024-04-30 | |||
| 2023-12-31 | 4.62% 10-K · filed 2026-02-24 | |||
| 2023-09-30 | 4.61% 10-Q · filed 2023-10-31 | |||
| 2023-06-30 | 3.85% 10-Q · filed 2023-08-01 | |||
| 2023-03-31 | 3.63% 10-Q · filed 2023-05-02 | |||
| 2022-12-31 | 4.05% 10-K · filed 2025-02-25 | |||
| 2022-09-30 | 4.05% 10-Q · filed 2022-11-01 | |||
| 2022-06-30 | 3.33% 10-Q · filed 2022-08-02 | |||
| 2022-03-31 | 2.37% 10-Q · filed 2022-05-03 | |||
| 2021-12-31 | 1.44% 10-K · filed 2023-02-21 | |||
| 2021-09-30 | 1.19% 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | 1.19% 10-Q · filed 2021-08-10 | |||
| 2021-03-31 | 1.19% 10-Q · filed 2021-05-11 | |||
| 2020-12-31 | 0.56% 10-K · filed 2023-02-21 | |||
| 2020-09-30 | 0.51% 10-Q · filed 2020-11-12 | |||
| 2019-12-31 | 2.59% 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |